Historical Valuation
CARDIOFLOW-B (02160) is now in the Overvalued zone, suggesting that its current forward PS ratio of 13.23 is considered Overvalued compared with the five-year average of -293.22. The fair price of CARDIOFLOW-B (02160) is between 0.26 to 0.48 according to relative valuation methord. Compared to the current price of 1.14 USD , CARDIOFLOW-B is Overvalued By 139.78%.
Relative Value
Fair Zone
0.26-0.48
Current Price：1.14
139.78%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
CARDIOFLOW-B (02160) has a current Price-to-Book (P/B) ratio of 1.24. Compared to its 3-year average P/B ratio of 1.26 , the current P/B ratio is approximately -1.58% higher. Relative to its 5-year average P/B ratio of 0.62, the current P/B ratio is about 99.21% higher. CARDIOFLOW-B (02160) has a Forward Free Cash Flow (FCF) yield of approximately -6.46%. Compared to its 3-year average FCF yield of -9.57%, the current FCF yield is approximately -32.43% lower. Relative to its 5-year average FCF yield of -6.77% , the current FCF yield is about -4.46% lower.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of 02160 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 02160 in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is 02160 currently overvalued or undervalued?
CARDIOFLOW-B (02160) is now in the Overvalued zone, suggesting that its current forward PS ratio of 13.23 is considered Overvalued compared with the five-year average of -293.22. The fair price of CARDIOFLOW-B (02160) is between 0.26 to 0.48 according to relative valuation methord. Compared to the current price of 1.14 USD , CARDIOFLOW-B is Overvalued By 139.78% .
What is CARDIOFLOW-B (02160) fair value?
02160's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of CARDIOFLOW-B (02160) is between 0.26 to 0.48 according to relative valuation methord.
How does 02160's valuation metrics compare to the industry average?
The average P/S ratio for 02160's competitors is , providing a benchmark for relative valuation. CARDIOFLOW-B Corp (02160) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for CARDIOFLOW-B (02160) as of Jan 16 2026?
As of Jan 16 2026, CARDIOFLOW-B (02160) has a P/B ratio of 1.24. This indicates that the market values 02160 at 1.24 times its book value.
What is the current FCF Yield for CARDIOFLOW-B (02160) as of Jan 16 2026?
As of Jan 16 2026, CARDIOFLOW-B (02160) has a FCF Yield of -6.46%. This means that for every dollar of CARDIOFLOW-B’s market capitalization, the company generates -6.46 cents in free cash flow.
What is the current Forward P/E ratio for CARDIOFLOW-B (02160) as of Jan 16 2026?
As of Jan 16 2026, CARDIOFLOW-B (02160) has a Forward P/E ratio of 121.96. This means the market is willing to pay $121.96 for every dollar of CARDIOFLOW-B’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for CARDIOFLOW-B (02160) as of Jan 16 2026?
As of Jan 16 2026, CARDIOFLOW-B (02160) has a Forward P/S ratio of 13.23. This means the market is valuing 02160 at $13.23 for every dollar of expected revenue over the next 12 months.